Management
ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership who proved their scientific excellence and financiers with deep understanding of pharma business.
Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer
- Founder of Vonderscher&Co GmbH
- Senior executive with a broad R&D experience in the pharmaceutical industry
- Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
- Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
- Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
- Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
- Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
- Board member of Inatherys, Step Pharma and ObsEva and SAB member of Inotrem SA
- Board member of LyonBiopôle and IMI-JU (Innovative Medicines Initiative-Joint Undertaking)
Dr Pietro Scalfaro, MD, MBA, SVP Head of Clinical Development Chief Medical Officer
- In charge of strategy and operational management of the clinical drug programs
- Wide range experience in various roles in the healthcare sector, working notably in infectious diseases (HCV, via the development of Alisporivir), septicaemia, oncology, Alzheimer’s disease and cardio-respiratory diseases
- Set up a Personalised Medicine Business Unit at Debiopharm Group and involved during start-up of eHealth and diagnostic companies (Biocartis, Sophia Genetics, Agendia, Immunexpress, Pryv, Orphanalytics)
- Practicing physician, with degrees from the University of Lausanne and the Swiss Medical Association in Paediatrics, Intensive Care and MBA
Dr Raphaël Darteil, PhD, SVP Head of non-clinical Development & Profiling
- Responsible for non-clinical development and in vitro / in vivo compound profiling
- More than 20 years of experience in R&D project and portfolio management in the Pharma and Biotech industries
- Scientific expertise in metabolic diseases (including NAFLD/NASH) and in the Nuclear Receptor field
- COO and Member of the board at Genfit
- Various positions in the department of Gene Therapy of Aventis both in France and in the US
- Co-inventor of the patent protecting the use of Elafibranor (Phase III) for the treatment of NASH patients
- He owns a PhD in Molecular and Cellular Biology from the University Claude Bernard Lyon I
Keltoum Medji, MBA, VP Finance and Strategic Development
- Responsible for all finance activities including fundraising, investors relations, strategic partnerships
- More than 20 years’ experience in Orthopedic business supporting growth by an increased collaboration with supply chain & commercial organizations
- Strong experience in change management through diverse organizational changes as M&A, restructuring, reorganizations
- Graduated with a Master’s degree in Economics & Business Management and an MBA from EM Lyon Business School
Claudi Miquel, VP Legal Affairs & Board Secretary
- Responsible for all legal affairs and Secretary of the Board of Directors
- 15 years’ experience as an attorney as well as lead counsel for international organizations across different jurisdictions
- Experience in transactional, financing, IP, and corporate/governance matters
- Graduated with a master’s degree in business law from Vanderbilt University law school
Pete Leone, MBA, Head of Business Development & Licensing
- Responsible for Business development
- More than 30 years of C-level experience at public and private biopharmaceutical companies, with over $6 billion in upfront payments and potential milestones from business development transactions that he led to closure
- Various management roles at Arrowhead Pharmaceuticals (Nasdaq: ARWR), including business development, was CBO at Bicycle Therapeutics (Nasdaq: BCYC), and previously, a cofounder of three venture-backed companies, including Mersana Therapeutics (Nasdaq: MRSN)
- Corporate and not-for-profit board member, including SeromYx Systems, Third Monday Foundation, and Nuestros Pequeños Hermanos – NPH USA Northeast region
- Holds an A.B. in engineering science with pre-med studies from Dartmouth College and an MBA from the Stanford University Graduate School of Business
Thomas Hess, CPA & MBA, Chief Financial Officer
- Responsible for all financial and accounting activities
- 35 years of experience in financial and executive management including: 10 years of publice accounting at KPMG and 13 years with emerging and growth-stage life science companies
- Significant experience in public and private capital raising for healthcare companies
- Currently serving as a Consulting CFO for Danforth Advisors LLC
- Previously CFO of several healthcare companies including: Adolor (Nasdaq: ADLR), Yaupon Therapeutics and Genomind, Inc.
- Education: University of Pittsburgh (MBA) and Pennsylvania State University (BS in Accounting)
Founders of ENYO Pharma
Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer
- Founder of Vonderscher&Co GmbH
- Senior executive with a broad R&D experience in the pharmaceutical industry
- Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
- Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
- Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
- Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
- Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
- Board member of Inatherys, Step Pharma and ObsEva and SAB member of Inotrem SA
- Board member of LyonBiopôle and IMI-JU (Innovative Medicines Initiative-Joint Undertaking)
Laurène Meyniel-Schicklin, Engineer, co-founder and Head of Bioinformatics
- 15 years experience in omics data management and analysis for drug discovery Team and project leader, responsible for bioinformatics, scientific data management and analysis
- Engineer in Biology and Computer Science (Genopole, Evry)
- 20 publications, inventor on 3 patents
- Forbes: Top 50 Women in Tech 2018
Dr Benoît de Chassey, PhD, co-founder and Head of Drug Discovery Platform
- Responsible for the drug discovery plateform of ENYO Pharma
- 18 years experience in high-throughput approaches in drug discovery
- Former project leader in functional screenings at Aptanomics
- 23 publications, inventor on 14 patents
Pr Patrice André, MD, PhD, co-founder and Medical Advisor
- Professor Emeritus of Virology at Charles Mérieux Lyon Sud Medical School, Lyon 1 University
- Former Head of clinical virology department at the Hospices Civils de Lyon
- Former Team leader at the International Center for Infectiology Research, Inserm, CNRS, ENS Lyon
- > 200 publications in international peer review and high-impact journals, inventor on 7 patents
- Co-founder and President of Hormae Pharma
Dr Vincent Lotteau, PhD, co-founder and Scientific Advisor
- Inserm Research Director, Immunologist
- Team leader at the International Center for Infectiology Research
- Former director of Inserm Unit « Fundamental and clinical immunology »
- Participated to several governmental missions
- Post-doctoral fellow at Harvard University and Scripps Clinic Research Foundation
- > 100 publications, Inventor on 11 patents
- Co-founder of Hormae Pharma
Dr Jean-Jacques Garaud, MD, co-founder
- CEO of Inotrem SA from 2013 to 2021
- Executive vice-president Medical and Scientific Affairs, Inotrem SA
- A senior executive with a broad R&D experience in the pharmaceutical industry
- Most recently Executive VP Head of Pharma Research and Early Development at Roche (2010 to 2012)
- Executive VP Head of Development and Chief Medical Officer at Roche (2007 to 2010)
- Previously held other senior positions with Shering-Plough in the USA (1991 to 2001) and with Novartis in the USA and Switzerland (2001 to 2007)
- Known for his leading role in the development of Interferon alpha, ribavirin and PEG-interferon in hepatitis C virus in the 90s
Inserm Transfert Initiative, co-founder
- Created in 2005, Inserm Transfert Initiative is a seed-capital company with € 39.7 M capital, further to its second fund raising in 2012.
- It focuses on providing seed capital for innovative young companies in the biomedical field. Inserm Transfert Initiative supports biotech entrepreneurs in the early stages of their companies’ development.
- Its current shareholders are BPI France, Inserm Transfert SA, AbbVie, Boehringer Ingelheim Venture Fund, GlaxoSmithKline, Ipsen, LFB, MSD (Merck & Co), Pfizer, Sanofi, SHAM, Shire.